We evaluated attitudes toward treatment as prevention (TasP) among gay, bisexual, and other men who have sex with men (GBM) in Vancouver, Canada.
Sexually active GBM, aged ≥16 years, were recruited between 2012 and 2015 using respondent-driven sampling. At each 6-month follow-up, participants completed a computer-administered questionnaire and nursing visit. Repeated-measures latent class analysis, grouped by self-reported serostatus, identified patterns of TasP endorsement by considering TasP-related awareness, attitudes, and behavior. Binary logistic regression identified covariates of class membership. Bivariate interactions with visit number identified factors associated with longitudinal changes in class membership.
A total of 774 men provided 2590 observations. Of these, 698 enrolled in the cohort, 575 had at least 1 follow-up visit. Among these, the median follow-up time was 1.98 years (Q1–Q2: 1.49–2.49 years). Repeated-measures latent class analysis identified 3 classes: “unaware” (64.2% HIV negative/unknown vs. 29.2% of HIV positive), “skeptical” (29.7% vs. 23.1%), and “believing” (6.1% vs. 47.7%). Membership in classes representing higher TasP endorsement was associated with greater odds of condomless anal sex and having more sexual partners. Age, sexual orientation, ethnicity, substance use, and social time spent with other GBM were also associated with class membership. Longitudinally, class membership was stable among HIV-positive men but shifted toward greater TasP endorsement among HIV-negative/unknown men. For HIV-negative/unknown men, increasing endorsement was positively associated with greater education, being employed, being in a relationship, and substance use and inversely associated with recent serodiscordant condomless anal sex or sexually transmitted infection diagnosis.
Over time, disparities in TasP diffusion by HIV status have lessened, although continue to persist across other key social strata.
*British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada;
†Faculty of Health Science, Simon Fraser University, Vancouver, BC, Canada;
‡Department of Medicine, University of British Columbia, Vancouver, BC, Canada;
§School of Public Health and Social Policy, University of Victoria, Victoria, BC, Canada;
‖Centre for Addiction Research of British Columbia, University of Victoria, Victoria, BC, Canada; and
¶Department of Anthropology, University of Victoria, Victoria, BC, Canada.
Correspondence to: Kiffer G. Card, BSc, Faculty of Health Sciences, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 1S6, Canada (e-mail: firstname.lastname@example.org).
Momentum is funded through the National Institute on Drug Abuse (R01DA031055-01A1) and the Canadian Institutes for Health Research (MOP-107544, 143342, PJT-153139). N.J.L. was supported by a CANFAR/CTN Postdoctoral Fellowship Award. D.M.M. and N.J.L. are supported by Scholar Awards from the Michael Smith Foundation for Health Research (Nos. 5209, 16863). J.S.G.M. is supported with grants paid to his institution by the British Columbia Ministry of Health and by the US National Institutes of Health (R01DA036307). J.S.G.M. has also received limited unrestricted funding, paid to his institution, from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. A.C. received support through a Doctoral Research Award from the CIHR HIV/AIDS Research Initiative and the Canadian Association for HIV Research (CAHR). H.L.A. is supported by a Postdoctoral Fellowship Award from the Canadian Institutes of Health Research (Grant No. MFE-152443). The remaining authors have no funding or conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
Received February 21, 2017
Accepted September 11, 2017